Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 742 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR What Is Mindfulness and How Can It Help People With Cancer? July 5, 2022 Listening to Patient Narratives June 9, 2020 How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives December 14, 2023 Black Women Have Nearly Three Times the Risk of Developing Triple... September 22, 2021 Load more HOT NEWS Pembrolizumab Combinations Show Promise in mCRPC How radiotherapy became a lifesaver – from X-rays to the proton... New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage... Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer
